On September 3, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806, hereinafter referred to as "Trinomab") reached another significant milestone!

Following the approval of Xintituo® (Generic Name: Stedostat Monoclonal Antibody Injection), the world's first innovative next-generation "tetanus shot," the company's independently developed global first recombinant anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Xinduotuo® (Generic Name: Ritevimab Monoclonal Antibody Injection, formerly known as TNM001 Injection) — has officially received marketing approval from the National Medical Products Administration (NMPA).

Xinduotuo® is indicated for the prevention of lower respiratory tract infection caused by RSV in neonates and infants who are about to enter or were born in their first RSV season. With this approval, a new option is now available for passive immunity against RSV in all neonates and infants: as a fully human monoclonal antibody with 9-month protection data, it requires only a single injection without weight-based dose adjustment — one shot covers the entire RSV season.

Efung Capital participated in Trinomab's financing round in 2023. Looking ahead, Efung Capital will continue to follow the progress of Trinomab's pipeline in respiratory infection prevention and fully human antibody therapeutics, and remain committed to supporting more innovative medicines in reaching patients in need.

END

Disclaimer: This article reflects the views of Efung Capital based on currently available public information and materials provided by the portfolio company, and does not constitute investment advice, medical advice, or a guarantee of any company's performance. Investment involves risk; please exercise caution and make independent judgments based on public information. Reproduction or commercial use without authorization is prohibited.